Biora Therapeutics, Inc. (NASDAQ:BIOR) Sees Significant Increase in Short Interest

Biora Therapeutics, Inc. (NASDAQ:BIOR) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 2,010,000 shares, a growth of 21.8% from the August 15th total of 1,650,000 shares. Approximately 5.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 194,200 shares, the short-interest ratio is presently 10.4 days.

Biora Therapeutics Price Performance

Shares of BIOR traded down $0.00 during mid-day trading on Tuesday, hitting $0.65. The company’s stock had a trading volume of 11,268 shares, compared to its average volume of 318,595. The firm has a 50-day moving average price of $0.67 and a 200 day moving average price of $0.75. Biora Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $2.71. The stock has a market capitalization of $23.52 million, a price-to-earnings ratio of -0.09 and a beta of 1.24.

Biora Therapeutics (NASDAQ:BIOR) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.10. The business had revenue of $0.32 million during the quarter. As a group, equities analysts anticipate that Biora Therapeutics will post -1.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Biora Therapeutics in a research note on Tuesday, August 13th.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.